



PCT/EP2004 / 003806

REC'D 19 MAY 2004	
WIPO	PCT INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ


I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed 
Dated 20 January 2004


BEST AVAILABLE COPY

Patents Form 1/77

Patents Act 1977
(Rule 16)

**The
Patent
Office**

11 APR 83 E799504-1-000524
P01/0700 0200-0308335.9



Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)

The Patent Office

Cardiff Road
Newport
Gwent NP10 8QQ

1. Your reference **4-33162P1**

2. Patent application number
(The Patent Office will fill in this part) **0.308.335.9** **10 APR 2003**

3. Full name, address and postcode of the
or of each applicant
(underline all surnames) **NOVARTIS AG**
LICHTSTRASSE 35
4056 BASEL
SWITZERLAND

Patent ADP number (if you know it)

If the applicant is a corporate body,
give the country/state of its
incorporation **SWITZERLAND**

7125487005

4. Title of invention **Organic Compounds**

5. Name of your agent (If you have one).

Novartis Pharmaceuticals UK Ltd
Patents and Trademarks
Wimblehurst Road
HORSHAM
West Sussex
RH12 5AB ADP No 0718522002

ice

B.A. YORKE & CO.
CHARTERED PATENT AGENTS
COOMB HOUSE, 7 ST. JOHN'S ROAD
ISLEWORTH
MIDDLESEX TW7 6NH

1800001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day/month/year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day/month/year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

(see note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document


Continuation sheets of this form

Description 43

Claim(s) 3

Abstract 1

Drawing(s)



10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*) 1

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

Date

B. A. Yorke & Co.

B.A. Yorke & Co.

10th April 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Mrs. S. Schnerr
020 8560 5847

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Organic Compounds

Retinoid X receptors (RXRs), belonging to the nuclear receptors superfamily, act as ligand-inducible transcriptional factors [Nagpal et al., Cell, 70: 1007-19 (1992); Kastner et al., Cell, 78:987-1003 (1995)]. RXRs regulate a wide variety of biological functions as a heterodimeric partner for other nuclear receptors (e.g. peroxisome proliferator-activated receptors: PPARs, liver X receptor: LXR, farnesoid X receptor: FXR and retinoic acid receptors: RARs) [Mangelsdorf et al., Cell, 83:841-50 (1995)].


EP906'907 (Institute of Medicinal Molecular Design (IMMD)) describes certain benzodiazepine derivatives, such as HX531 and HX600, as compounds with an affinity to the retinoid X receptor (RXR). EP906'907 further teaches that the addressed compounds shall be in particular useful for the preventive or therapeutic treatments of vitamin A deficiency disease, hyperkeratosis of epithelial tissue, psoriasis, allergic diseases, immunological diseases such as rheumatism, bone diseases, leukemia, or cancers, the compounds of the present invention can be used as agents that enhance the activities of the retinoids.

EP 1'036'565 (IMMD) describes similar benzodiazepines as in EP906'907 which shall be useful for therapeutic and/or preventive treatment of: Diabetes, the complications of diabetes such as retinopathy, nephropathy, neuropathy and hyperlipidemia, with reduced or no side effect such as hypoglycemic shock.

The present invention relates to novel benzodiazepine compounds exhibiting RXR-antagonist efficacy, to the manufacture and to the use of RXR antagonists. The class of RXR-antagonists, which have in particular the ability to reduce the body weight in an individual, for example as exemplified in the KKA^y in vivo mice model according to the present invention are represented by formula (I). Moreover, the RXR antagonists of the present invention may be useful in the delay of progression of / prevention of / treatment of a disease or condition selected from the group consisting of diabetes; type-2-diabetes; complication of diabetes such as retinopathy, nephropathy, neuropathy, and hyperlipidemia; obesity; dyslipidemia; and osteoporosis.

The compounds of the present invention typically exhibit favorable pharmacological profile e.g. an unexpected superior RXR-affinity, with a pronounced in vivo efficacy, e.g. in reducing effectively the body weight.

Accordingly, the present invention relates to benzodiazepine compounds of formula (I) or a pharmaceutically acceptable salt thereof,




wherein R_1 and R_2 , independently of each other, represent hydrogen, or C_1 - C_7 -alkyl, or R_1 and R_2 together with the carbon atoms of the phenyl ring to which they bind form a 5-, 6- or 7-membered cycloalkyl ring, which ring may optionally be substituted by one or more C_1 - C_7 -alkyl groups, which alkyl groups may also together form one or more 3-, 4-, 5-, 6- or 7-membered rings;

R_3 represents $-CN$, $-CO-R_5$, or hydrogen, provided that, if R_3 is hydrogen, R_4 must represent C_2 - C_7 -alkenyl or C_2 - C_7 -alkinyl;

R_5 represents aryl, or alkyl being unsubstituted or substituted by halogen, cyano, nitro, hydroxy, C_1 - C_7 -alkoxy, carboxyl or aryl.

R_4 represents C_1 - C_7 -alkyl, C_2 - C_7 -alkenyl or C_2 - C_7 -alkinyl or R_4 represents C_2 - C_7 -alkanoyl;

X represents ligand (a)



wherein Y may be in ortho, meta or para position and wherein Y represents carboxyl, C_1 - C_7 -alkoxy-carbonyl, aryloxy-carbonyl, tetrazolyl, SO_3H or $P(O)(OH)_2$; and wherein Z represents hydrogen or a substituent selected from the group consisting of C_1 - C_7 -alkyl, C_1 - C_7 -alkoxy, halogen, CF_3 , cyano, and NO_2 .

If compounds according to the invention may have at least two optically active carbon atoms, they may accordingly be present in the form of stereoisomers, stereoisomer mixtures and also in the form of (essentially) pure diastereoisomers. Corresponding compounds with an optically active carbon atom are present as racemates, primarily as (essentially pure) enantiomers. Corresponding stereoisomers are similarly embraced by the present invention.

Unless otherwise defined, the general terms used hereinabove and hereinbelow have the meanings given hereinbelow.

Alkyl as used herein has up to 14 carbon atoms, is linear, branched, cyclic or a combination thereof and is preferably C₁-C₇-alkyl, more preferably linear or branched C₁-C₇-alkyl, more specifically methyl, ethyl, n-propyl, isopropyl, cyclopropyl, methylcyclopropyl, cyclopropylmethyl, cyclobutyl, iso-butyl or tert-butyl. Alkyl is preferably C₁-C₇-alkyl.


C₁-C₇-Alkyl is preferably C₁-C₅-alkyl, most preferably C₁-C₃-alkyl and is in particular methyl, ethyl, n-propyl, and isopropyl, and especially methyl and ethyl.

C₂-C₇-Alkenyl is in particular C₃-C₇-alkenyl and is, for example, 2-propenyl or 1-, 2- or 3-butenyl. C₃-C₅-alkenyl is preferred, especially preferred is allyl.

C₂-C₇-Alkynyl is in particular C₃-C₇-alkynyl and is preferably propargyl.

5- to 7-Membered cycloalkyl is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Cyclopropyl, Cyclopentyl and cyclohexyl are preferred.

3- to 7-Membered rings, formed by R₁ and R₂ together with the carbon atoms of the phenyl ring to which they are attached, are, for example, represented by following partial structures:



C₁-C₇-Alkoxy is, for example, C₁-C₅-alkoxy, preferably C₁-C₃-alkoxy, such as methoxy, ethoxy, propyloxy, isopropyloxy or butyloxy, but may also be isobutyloxy, sec-butyloxy, tert-butyloxy or a pentyloxy, hexyloxy or heptyloxy group. Preferred is methoxy and ethoxy.

As used herein halogen is preferably fluorine, chlorine, bromine, or iodine, more preferably fluorine, or chlorine, highly preferably fluorine.

As used herein, aryl stands for a carbocyclic aromatic moiety having from 6 to 14 carbon atoms, and is for example, phenyl or naphthyl or biphenyl that is unsubstituted or substituted by C₁-C₇-alkyl, C₁-C₇-alkoxy, hydroxy, C₁-C₇-alkoxy-carbonyl, carboxy, carbamoyl, sulfamoyl, C₂-C₇-alkanoyl, halogen and/or by trifluoromethyl. Aryl as used herein stands also for an unsubstituted or substituted heteroaromatic radical optionally partially hydrogenated, 5- or 6-membered monocyclic heteroaryl or bicyclic heteroaryl composed of 5- or 6-membered rings, such as corresponding furyl, C₁-C₇-alkylfuryl, for example 4-methylfur-2-yl, thienyl, imidazolyl, for example imidazol-4-yl, oxazolyl, carboxy-C₁-C₇-alkyl(oxo)oxazolyl, for example 2,5-dihydro-3-oxo-1,2-oxazolyl, thiazolyl, dihydrothiazolyl, for example 4,5-dihydrothiazolyl, carboxy-C₁-C₇-alkylthiazolyl, for example 4-carboxymethylthiazolyl, C₂-C₇-alkoxycarbonyl-C₁-C₇-alkylthiazolyl, for example 4-methoxycarbonylmethylthiazolyl or 4-ethoxycarbonylmethylthiazolyl, tetrazolyl, pyridyl, pyrazinyl, indolyl, for example indol-3-yl, quinolinyl, for example quinolin-4-yl, benzazepinyl or carboxy-C₁-C₇-alkyl-2,3,4,5-tetrahydro-1H-1-benzazepino, for example 1-carboxymethyl-2,3,4,5-tetrahydro-1H-1-benzazepino. Preferably, aryl is phenyl, pyridyl, thienyl or naphthyl that is unsubstituted or substituted by C₁-C₇-alkyl, C₁-C₇-alkoxy, hydroxy, carboxy, carbamoyl, sulfamoyl, C₂-C₇-alkanoyl, halogen and/or by trifluoromethyl. Representatives of corresponding heteroaryl comprise furyl, e.g. 2- or 3-furyl; thienyl, e.g. 2- or 3-thienyl; pyrrolyl, e.g. 1-, 2- or 3-pyrrolyl; oxazolyl, e.g. 2-, 4- or 5-oxazolyl, e.g. 2-, 4- or 5-oxazolyl;

isoxazolyl, e.g. 3- or 4-isoxazolyl; imidazolyl, e.g. 2-, 4- or 5-imidazolyl; thiazolyl, e.g. 2-, 4- or 5-thiazolyl; isothiazolyl, e.g. 3- or 4-isothiazolyl; pyranyl, e.g. 2- or 3-pyranyl; pyridyl, e.g. 2- or 3-pyridyl; pyrazinyl, e.g. 3- or 4-pyrazinyl; pyrimidinyl, e.g. 2- or 4-pyrimidinyl; pyridazinyl, e.g. 2- or 3-pyridazinyl; tetrazoyl, e.g. tetrazol-5-yl.

C₂-C₇-Alkoxy-carbonyl is, for example, preferably C₂-C₅alkoxycarbonyl, such as methoxycarbonyl, ethoxycarbonyl, propyloxycarbonyl, isopropyloxycarbonyl or butyloxycarbonyl, but may also be isobutyloxycarbonyl, sec-butyloxycarbonyl, tert-butyloxycarbonyl or a pentyloxycarbonyl, hexyloxycarbonyl or heptyloxycarbonyl group. Preferred is methoxy- or ethoxy-carbonyl.

Aryloxycarbonyl is, for example, phenyloxycarbonyl, naphthyloxycarbonyl such as 1- or 2-naphthyloxycarbonyl, or pyridyloxycarbonyl such as 2-, 3- or 4-pyridyloxycarbonyl.

C₁-C₇-Alkoxy-carbonylcycloalkyl is, for example, C₁-C₅alkoxy-carbonylcycloalkyl, preferably C₁-C₃alkoxy-carbonylcycloalkyl, such as methoxycarbonylcycloalkyl, ethoxycarbonyl-carbamoylcycloalkyl, propyloxycarbonylcycloalkyl, isopropyloxycarbonylcycloalkyl or butyloxycarbonylcycloalkyl, wherein cycloalkyl is, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.


C₂-C₇-Alkoxycarbonyl-C₁-C₇-alkyl is, for example, C₂-C₅alkoxycarbonyl-C₁-C₅alkyl, preferably C₂-C₃alkoxycarbonyl-C₁-C₃alkyl, such as methoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylmethyl, ethoxycarbonylethyl, methoxycarbonylpropyl, ethoxycarbonylpropyl, propyloxycarbonylmethyl, propyloxycarbonylethyl, isopropyloxycarbonylmethyl, isopropyloxycarbonylethyl or butyloxycarbonylmethyl.

C₂-C₇-Alkoxycarbonyl-C₁-C₇-alkylene is, for example, C₂-C₅alkoxycarbonyl-C₂-C₅alkylene, preferably C₂-C₃alkoxycarbonyl-C₂-C₃alkylene, such as 1-methoxycarbonylethylene, 1-ethoxycarbonylethylene, 1,3-(methoxycarbonyl)propylene, 1,3-(ethoxycarbonyl)propylene, 1,3-(propyloxycarbonyl)propylene, 1,3-(butyloxycarbonyl)propylene, 1,3-(sec-butyloxycarbonyl)propylene or 1,3-(tert-butyloxycarbonyl)propylene.


C₁-C₇-Alkoxy-C₁-C₇-alkyl is, for example, C₂-C₅-alkoxy-C₁-C₅alkyl, such as 2-methoxyethyl, ethoxymethyl, 2-methoxyethyl, 2-ethoxyethyl, 3-methoxypropyl or 4-methoxybutyl.

C₂-C₇-Alkanoyl is, for example, C₂-C₅alkanoyl, preferably, C₂-C₃alkanoyl, such as acetyl, propionyl, butyryl, likewise pivaloyl. Most preferred is acetyl.


R₁ and R₂ independently represent hydrogen or a linear or branched C₁-C₇-alkyl group. As for the C₁-C₇-alkyl group, those mentioned above may be used, and ethyl group, isopropyl group, tert-butyl group or the like may preferably be used. The substituting positions of R₁ and R₂ are not particularly limited, and each of them may independently substitute at any position. However, it is preferred that R₁ and R₂ are at para-position and meta-position with reference to N-R₄, respectively, or R₁ and R₂ are at meta-position and ortho-position with reference to N-R₄. It is particularly preferred that R₁ and R₂ are at para-position and meta-position with reference to N-R₄, respectively. It is especially preferred that R₁ and R₂ are as illustrated in formula (II a).



R₁ and R₂ may combine to form a 5-, 6- or 7-membered cycloalkyl ring together with two carbon atoms on the phenyl ring to which R₁ and R₂ respectively bind. The cycloalkyl ring may have one or more C₁-C₇-alkyl groups, in particular C₁-C₅-alkyl. For example, such a cycloalkyl ring may have from two to four methyl groups, preferably four methyl groups. It is preferred that, for example, R₁ and R₂ together with the phenyl ring substituted with R₁ and R₂ form 5,6,7,8-tetrahydronaphthalene ring or 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene ring, as illustrated in formula (II c).




(II b)




(II c)

As exemplified in formula (IIb), R_1 and R_2 may form a 5-, 6- or 7-membered ring ($A=CH_2$, CH_2CH_2 , or $CH_2CH_2CH_2$), preferably a 5- or 6-membered ring ($A = CH_2$, or CH_2CH_2), in particular a 6-membered ring, optionally substituted by one or more C_1-C_7 -alkyl (alk = C_1-C_7 -alkyl), which C_1-C_7 -alkyl group may again combine with C_1-C_7 -alkyl to represent a cycloalkyl ring, e.g. spirocyclic, such as cyclopropyl, cyclobutyl or cyclohexyl. In another preferred aspect said combined C_1-C_7 -alkyl residues form a 3- to 7-membered cycloalkyl, especially cyclopropyl, preferably as illustrated in formula (II d).



(II d).

X represents preferably o-phenylene, m-phenylene, or p-phenylene substituted by Y. More preferably, X represents p-phenylene substituted by Y, as indicated in formula (b).



(b)

Y represents preferably carboxyl, C_1-C_7 -alkoxy-carbonyl, aryloxycarbonyl, tetrazolyl, SO_3H , more preferably carboxyl, tetrazolyl, especially tetrazol-5-yl, or $P(O)(OH)_2$, even more preferably carboxyl, or tetrazolyl, especially tetrazol-5-yl, in particular carboxyl. Y preferably is carboxy. Z is hydrogen or a substituent selected from the group consisting of C_1-C_7 -alkyl,

C₁-C₇-alkoxy, halogen, CF₃, cyano, and NO₂; especially preferred is halogen, most preferably fluorine.

Highly preferably, X represents p-carboxyl-phenyl.

R₄ represents C₁-C₇-alkyl, C₃-C₇-alkenyl or C₃-C₇-alkinyl. More preferably R₄ represents C₁-C₅-alkyl, even more preferably C₁-C₃-alkyl. In particular, R₄ is CH₃ or C₂H₅.

In another aspect R₄ represents C₃-C₇-alkenyl or C₃-C₇-alkinyl, provided R₃ represents hydrogen. A more preferred alkenyl is allyl. A preferred alkinyl is propargyl. Highly preferred substituents R₄ are allyl and propargyl, provided R₃ = hydrogen.

R₃ represents -CN, or -CO-R₅. R₃ may also represent hydrogen, provided however R₄ represents C₃-C₇-alkenyl or C₃-C₇-alkinyl.

R₅ represents aryl, or alkyl being unsubstituted or substituted by halogen, cyano, nitro, hydroxy, C₁-C₇-alkoxy, carboxyl or aryl.

The position of R₃ in the phenyl ring is not particularly limited, thus it may be at any position of the phenyl ring. A preferred position is the para-position relative to N-R₄ in general formula (I).

Preferred examples of the aryl moiety include phenyl, pyridyl, thienyl, naphthyl that is, in each case, unsubstituted or substituted by one or more, e.g. two, substituents selected from the group consisting of C₁-C₇-alkyl, C₁-C₇-alkoxy, hydroxy, carboxy, carbamoyl, sulfamoyl, C₂-C₇-alkanoyl, halogen and trifluoromethyl.

As for the alkyl group, C₁-C₇-alkyl is preferred, and the preferred examples may be used, in particular methyl, ethyl, propyl, butyl, isopropyl or the like.

Preferred examples of alkyl being substituted by halogen, cyano, nitro, hydroxy, alkoxy, or carboxyl include C₁-C₇-alkyl substituted by these and are, for example, fluoromethyl, fluoroethyl, difluoromethyl, trifluoromethyl, trichloroethyl, hydroxyethyl, hydroxypropyl, cyanomethyl, cyanoethyl, nitromethyl, methoxyethyl, and the like.

Preferred examples of the aryl moiety of the aryl-substituted alkyl group include, for example, phenyl, naphthyl, or pyridyl group, and the alkyl moiety may be either linear or branched and is preferably C₁-C₇-alkyl. For example, a phenyl-substituted C₁-C₇-alkyl group such as benzyl group or phenethyl group, a naphthyl-substituted C₁-C₇-alkyl group such as naphthylmethyl group, a pyridyl-substituted C₁-C₇-alkyl group such as pyridylmethyl group and the like can be used. The aryl group constituting these aryl-substituted C₁-C₇-alkyl groups may have one or more substituents. For example, a halogen atom such as fluorine atom or chlorine atom; a C₁-C₇-alkyl group such as methyl group or ethyl group; a linear or branched C₁-C₇-alkoxy group such as methoxy group or ethoxy group; nitro group; a cyano group, a linear or branched halogenated C₁-C₇-alkyl group such as trifluoromethyl group; hydroxyl group; carboxyl group; a C₂-C₇-alkoxycarbonyl group such as methoxycarbonyl.

More preferably R₅ represents methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, heptyl, phenyl, chlorophenyl, fluorophenyl, nitrophenyl, cyanophenyl, thienyl, pyridyl, benzyl, ethylphenyl, and the like.

Even more preferably, R₃ represents -CN, or -CO-R₅ wherein R₅ represents C₁-C₇-alkyl and in particular methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, heptyl. Highly preferably R₃ represents -CN, -CO-methyl, -CO-ethyl, -CO-propyl.

Preferred RXR-antagonists in accordance to the present invention are represented by formula (IIc),


R₃ is hydrogen and R₄ is C₃-C₇-alkenyl or C₃-C₇-alkinyl; or R₃ is cyano; C₂-C₇-alkanoyl; or benzoyl which is unsubstituted or substituted by a substituent selected from the group consisting of C₁-C₄-alkyl, C₁-C₄-alkoxy, hydroxy, halogen and trifluoromethyl; and R₄ represents C₁-C₄-alkyl, C₃-C₇-alkenyl, C₃-C₇-alkinyl, or C₂-C₅-alkanoyl; wherein X represents 4-carboxyphenyl, 2-halo-4-carboxyphenyl or 3-halo-4-carboxyphenyl, especially 2-fluoro-4-carboxyphenyl or 3-fluoro-4-carboxyphenyl.

Preferred RXR-antagonists in accordance to the present invention are represented by formula (IIc),

wherein X represents 4-carboxy-phenyl; R₃ is cyano; and R₄ represents C₁-C₇-alkyl, C₃-C₇-alkenyl or C₃-C₇-alkinyl. A preferred position for R₃ is the para-position relative to N-R₄ in formula (V). In a more preferred aspect R₄ represents C₁-C₇-alkyl. In a even more preferred

aspect, R_3 is cyano and is the para-position relative to NR_4 in formula (V) and R_4 represents C_1 - C_7 -alkyl. C_1 - C_7 -Alkyl represents in this context even more preferably methyl or ethyl.







Further preferred RXR-antagonists in accordance to the present invention are represented by formula (II e),



wherein X represents 4-carboxyphenyl; and R_4 represents C_3 - C_7 -alkenyl or C_3 - C_7 -alkinyl. A more preferred alkenyl is vinyl or allyl, in particular allyl. A preferred alkinyl is ethinyl or propargyl. Highly preferred substituents R_4 are allyl and propargyl.

Especially preferred is a compound of formula (II c) or a salt thereof, wherein R_3 is hydrogen and R_4 is C_3 - C_7 -alkenyl, especially allyl, C_3 - C_7 -alkinyl, especially propargyl, or C_3 - C_7 -alkanoyl, especially acetyl; or R_3 is cyano or C_2 - C_5 -alkanoyl, especially acetyl; and R_4 is C_1 - C_4 -alkyl, especially methyl, ethyl, C_3 - C_5 -alkenyl, especially allyl, C_3 - C_5 -alkinyl, especially propargyl, or C_2 - C_5 -alkanoyl, especially acetyl; and X is 4-carboxy-phenyl and the phenyl ring is otherwise unsubstituted or substituted by halogen, especially fluorine, preferably in position 2 or 3 of the phenyl ring; for example, X is 4-carboxy-phenyl, 4-carboxy-3-fluoro-phenyl or 4-carboxy-2-fluoro-phenyl.

The compounds of formulae (III a), (III b), (III c), (III d), (III e) and (III f) being disclosed infra, exhibit distinct RXR-antagonistic properties and are among the specifically preferred compounds:



The present invention also pertains to a method of delaying progression of, preventing of or treating a condition or disease being associated with RXR-antagonism, which method comprises the steps of administering an effective amount of a RXR antagonist, especially a compound of formula (I), or of a more preferred compound selected from the compounds according to formulae (II c), (V) and (VI), or a salt thereof, to a patient in need of such treatment, wherein said condition or disease associated with RXR-antagonism is preferably selected from the group consisting of diabetes, type-2-diabetes, complication of diabetes such as retinopathy, nephropathy, neuropathy, and hyperlipidemia, obesity, dyslipidemia, and osteoporosis.

As used herein the terms "treatment", "treating" or "treat" refer to both prophylactic or preventive treatment as well as curative or disease-modifying treatment, including treatment of patients at risk of contracting the disease or suspected to have contracted the disease as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition. Likewise, delay of progression of a condition or disease is comprised by the term "treatment" and the like.

The invention further pertains to the use of a compound according to formula (I) or a salt thereof, as an RXR-antagonist.

It also pertains to the use of a RXR-antagonist, in particular a compound of formula (I) or a salt thereof, in the manufacture of a medicament for delaying progression of, preventing of or treating a condition or disease being associated with RXR-antagonism, in particular selected from diabetes, type-2-diabetes, complication of diabetes such as retinopathy, nephropathy, neuropathy, and hyperlipidemia, obesity, dyslipidemia, and osteoporosis.

The invention also pertains to a pharmaceutical composition comprising a RXR antagonist, especially a compound of the present invention, in particular of formula (I), in association with a pharmacologically and pharmaceutically acceptable additive.

The invention also pertains to a pharmaceutical composition for delaying progression of, preventing of or treating a condition or disease being associated with RXR-antagonism, in particular selected from diabetes, type-2-diabetes, complication of diabetes such as retinopathy, nephropathy, neuropathy, and hyperlipidemia, obesity, dyslipidemia, and osteoporosis.

Compounds of formula I having acidic groups may form salts with bases. Compounds of formula I having basic groups may also form acid addition salts and, where in addition at least one acidic group is present, may also form internal salts.

Also included are both total and partial salts, that is to say salts with 1, 2 or 3, preferably 2, equivalents of base per mole of acid of formula I, or salts with 1, 2 or 3 equivalents, preferably 1 equivalent, of acid per mole of base of formula I.

For the purposes of isolation or purification it is also possible to use pharmaceutically unacceptable salts. Only the pharmaceutically acceptable, non-toxic salts (pharmaceutically acceptable salts) are used therapeutically and they are therefore preferred.

Combinations:

Another embodiment of the present invention relates to a combination, especially a pharmaceutical composition, comprising as active ingredients an RXR-antagonist or a pharmaceutically acceptable salt thereof, especially a compound of formula (I) as described hereinbefore and at least another pharmaceutically effective drug selected from the group consisting of:

Diuretics, alpha-receptor blockers, beta-receptor antagonists, vasodilating agents, calcium antagonists, renin inhibitors, angiotensin II antagonists, angiotensin converting enzyme inhibitors (ACE-inhibitors), insulin secretion enhancers and insulin sensitizers.

Preferred combinations relate to a combination of

- (i) an RXR-antagonist or a pharmaceutically acceptable salt thereof, especially a compound of formula (I) as described hereinbefore; and
- (ii) at least another active ingredient, selected from the group of:
 - (a) AT₁-receptor antagonist or a pharmaceutically acceptable salt thereof;
 - (b) Insulin secretion enhancer or a pharmaceutically acceptable salt thereof, and
 - (c) an insulin sensitizer or a pharmaceutically acceptable salt thereof.

In case of a pharmaceutical composition, a pharmaceutically acceptable carrier is typically contained as well.

Preferably, the jointly therapeutically effective amounts of the active agents according to the combination of the present invention can be administered simultaneously or sequentially in any order, e.g. separately or in a fixed combination.

Under certain circumstances, drugs with different mechanisms of action may be combined. However, just considering any combination of drugs having different modes of action but acting in the similar field does not necessarily lead to combinations with advantageous effects.

A typical experimental finding of the present invention is that the combined administration of an RXR-antagonist and an AT₁ receptor antagonist and/or insulin secretion enhancer and/or an insulin sensitizer, or, in each case, a pharmaceutically acceptable salt thereof, results not only in a beneficial, especially a potentiating or a synergistic, therapeutic efficacy. Independent thereof, additional benefits resulting from combined treatment can be achieved such as a surprising prolongation of efficacy, a broader variety of therapeutic treatment and surprising beneficial effects on diseases and conditions associated with diabetes and obesity, e.g. less gain of weight. An additional and preferred aspect of the present invention is the prevention, delay of progression or treatment of the condition of isolated systolic hypertension and impaired vascular compliance which means decreased vascular elasticity.

The term "potentiation" shall mean an increase of a corresponding pharmacological efficacy or therapeutical effect, respectively. Potentiation of one component of the combination according to the present invention by co-administration of an other component according to the present invention means that an effect is being achieved that is greater than that achieved with one component alone.

The term "synergistic" shall mean that the drugs, when taken together, produce a total joint effect which is greater than the sum of the effects of each drug when taken alone.

As used herein, AT₁-receptor antagonists (also called angiotensin II receptor antagonists or blockers) bind to the AT₁-receptor subtype of angiotensin II receptor but do not result in activation of the receptor. As a consequence of the blockade of the AT₁ receptor, these antagonists can, for example, be employed as antihypertensives or for treating congestive heart failure.

The class of AT₁ receptor antagonists comprises compounds having differing structural features, essentially preferred are the non-peptidic ones. Typically such compounds are selected from the group consisting of valsartan (cf. EP 443983), losartan (cf. EP 253310), candesartan (cf. EP 459136), eprosartan (cf. EP403159), irbesartan (cf. EP 454511), olmesartan (cf. US 5616599), tasosartan (cf. EP 539086), and telmisartan (cf. EP 502314), or, in each case, a pharmaceutically acceptable salt thereof.

Preferred AT₁-receptor antagonist are those agents that have been marketed, most preferred is valsartan or a pharmaceutically acceptable salt thereof.


A preferred renin inhibitor is aliskiren or a pharmaceutically acceptable salt thereof.

A preferred ACE-inhibitor is, for example, enalapril or enalaprilate, benazepril or benazeprilate, lisinopril or ramipril or, in each case, a pharmaceutically acceptable salt thereof.

Insulin secretion enhancers are active ingredients that have the property to promote the secretion of insulin from pancreatic β -cells. Examples of insulin secretion enhancers are

sulfonylureas (SU), especially those which promote the secretion of insulin from pancreatic β -cells by transmitting signals of insulin secretion via SU receptors in the cell membrane, including (but not limited to) tolbutamide; chlorpropamide; tolazamide; acetohexamide; 4-chloro-N-[(1-pyrrolidinylamino)carbonyl]-benzensulfonamide (glycopyramide); glibenclamide (glyburide); gliclazide; 1-butyl-3-metanilylurea; carbutamide; glibonuride; glipizide; gliquidone; glisoxepid; glybuthiazole; glibuzole; glyhexamide; glymidine; glypinamide; phenbutamide; and tolylcyclamide, or a pharmaceutically acceptable salt thereof.

Insulin secretion enhancers furthermore include short-acting insulin secretion enhancers, such as the new phenylalanine derivative nateglinide [N-(trans-4-isopropylcyclohexyl-carbonyl)-D-phenylalanine] (cf. EP 196222 and EP 526171) of the formula



repaglinide [(S)-2-ethoxy-4-{2-[[3-methyl-1-[2-(1-piperidiny)phenyl]butyl]amino]-2-oxoethyl}benzoic acid – cf. EP 589874] ; calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)-propionate dihydrate (mitiglinide – cf. EP 507534); furthermore representatives of the new generation of SUs such as glimepiride (cf. EP 31058); and in free or pharmaceutically acceptable salt form.

As used herein, insulin secretion enhancers include the long-acting insulin secretion enhancer DPP-IV inhibitors, GLP1 and GLP1 agonists.

DPP-IV is responsible for inactivating GLP-1. More particularly, DPP-IV generates a GLP-1 receptor antagonist and thereby shortens the physiological response to GLP-1. GLP-1 is a major stimulator of pancreatic insulin secretion and has direct beneficial effects on glucose disposal.

The DPP-IV inhibitor can be peptidic or, preferably, non-peptidic. DPP-IV inhibitors are in each case generically and specifically disclosed e.g. in WO 98/19998, DE 196 16 486 A1, WO 00/34241 and WO 95/15309, in each case in particular in the compound claims and the final products of the working examples, the subject-matter of the final products, the

pharmaceutical preparations and the claims are hereby incorporated into the present application by reference to these publications. Preferred are those compounds that are specifically disclosed in Example 3 of WO 98/19998 and Example 1 of WO 00/34241, respectively.

GLP-1 is a insulinotropic protein which was described, e.g., by W.E. Schmidt et al. in *Diabetologia* 28, 1985, 704-707 and in US 5,705,483.

The term "GLP-1 agonists" used herein means variants and analogs of GLP-1(7-36)NH₂ which are disclosed in particular in US 5,120,712, US 5,118,666, US 5,512,549, WO 91/11457 and by C. Orskov et al in *J. Biol. Chem.* 264 (1989) 12826. The term "GLP-1 agonists" comprises especially compounds like GLP-1(7-37), in which compound the carboxy-terminal amide functionality of Arg³⁶ is displaced with Gly at the 37th position of the GLP-1(7-36)NH₂ molecule and variants and analogs thereof including GLN⁹-GLP-1(7-37), D-GLN⁹-GLP-1(7-37), acetyl LYS⁹-GLP-1(7-37), LYS¹⁸-GLP-1(7-37) and, in particular, GLP-1(7-37)OH, VAL⁸-GLP-1(7-37), GLY⁸-GLP-1(7-37), THR⁸-GLP-1(7-37), MET⁸-GLP-1(7-37) and 4-imidazopropionyl-GLP-1. Special preference is also given to the GLP agonist analog exendin-4, described by Greig et al in *Diabetologia* 1999, 42, 45-50.

A preferred insulin secretion enhancer is repaglinide, most preferred is nateglinide.

The term nateglinide likewise comprises crystal modifications such as disclosed in EP 0526171 B1 or US 5,488,510, respectively, the subject matter of which, especially with respect to the identification, manufacture and characterization of crystal modifications, is herewith incorporated by reference to this application, especially the subject matter of claims 8 to 10 (being directed to the H-form crystal modification) as well as the corresponding references to the B-form crystal modification.

The structure of the active agents identified by generic or tradenames may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g. Patents International (e.g. IMS World Publications). The corresponding content thereof is hereby incorporated by reference. Any person skilled in the art is fully enabled to identify the active agents and, based on these references, likewise enabled to manufacture and test the pharmaceutical indications and properties in standard test models, both in vitro and in vivo.

The term "short-acting insulin secretion enhancer" comprises corresponding agents with a maximum secretion of insulin that is attained within one hour, preferably within 30 minutes, after the administration of the agent, most preferably within 20 minutes having a biological half-life, $T_{1/2}$, of less than two hours, preferably, 1.5 hours. The term long-acting insulin secretion enhancer" comprises corresponding agents with a maximum secretion of insulin that is attained more than one hour after administration of the agent.

A preferred insulin sensitizer is metformin or a pharmaceutically acceptable salt thereof such as the mono-hydrochloride.

Especially preferred is a combination of a preferred RXR-antagonist of the present invention with valsartan or a pharmaceutically acceptable salt thereof and/or nateglinide or a pharmaceutically acceptable salt thereof.

The corresponding active ingredients or a pharmaceutically acceptable salts thereof may also be used in form of a solvate, such as a hydrate or including other solvents, used for crystallization.

The compounds to be combined can be present as pharmaceutically acceptable salts. If these compounds have, for example, at least one basic center, they can form acid addition salts. Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center. The compounds having an acid group (for example COOH) can also form salts with bases.

The pharmaceutical activities as effected by administration of representatives of the class of RXR-antagonists of formula (I), or AT_1 -receptor antagonists or insulin secretion enhancers, respectively, or of the combination of active agents used according to the present invention can be demonstrated e.g. by using corresponding pharmacological models known in the pertinent art. The person skilled in the pertinent art is fully enabled to select a relevant animal test model to prove the hereinbefore and hereinafter indicated therapeutic indications and beneficial effects.

Experimental Part – Biology

1) *in vitro* model: Reporter gene assay


To determine the effects of an RXR-antagonist at the cellular level, a reporter gene assay is used to assess gene expression and regulation by an antagonist. A reporter gene assay for RXR α homodimer is performed using 9-cis-retinoic acid and LG100268, RXR selective ligand. HEK 293 cells are transfected with the hRXR α expression vector, pcDNA-hRXR α and reporter plasmid, pGL3proCRBP II. For assays, the cells are seeded in 96 well tissue culture plates. The next day, 9-cis-retinoic acid or LG100268 as the activating ligand are added to the medium in the presence or absence of RXR antagonists. After 20-24 h incubation, the cells are lysed and the luciferase activity is measured.

2) *in vivo* model: KKA^y mice

KKA^y mice [Iwatsuka et al., Endocrinol. Jpn., 17: 23-35 (1970)] are characterized by severe obesity and features of type 2 diabetes [Herberg et al., Metabolism, 26: 59-99, 1970, Hayase et al., Am. J. Physiol., 271: E333-9, 1996]. This animal model is useful to study the pathogenesis, therapy, and prevention of obesity and diabetes.

The efficacy of RXR-antagonists is determined in obese diabetic KKA^y mice using similar method described by Yamauchi et al. [J. Clin. Invest., 108: 1001-13, 2001]. Male 8-9 week old KKA^y mice pre-fed a high fat diet for 1-2 weeks are divided into the groups. RXR antagonists are administered as a food admixture for 1-2 weeks. Body weight and food intake are monitored during the administration. After the administration, blood samples are taken and the heparinized plasma samples are stored at -80°C after the centrifugation (4 °C, 1,500 times g, 10 min) for the measurement of plasma parameters. The parameters are measured using commercially available kits.

Highly preferred compounds so far based on the data observed in the *in vivo* KKA^y screening are highlighted infra:



3) *in vitro* model: RXR α binding assay

Varying concentrations of ^3H 9-cis-RA (retinoic acid) are incubated with or without 50 ng of full length glutathione-S-transferase (GST)-human RXR α for 18 hours at 4°C in 200 micro liter binding buffer under continuous rotation. After addition of 80 micro liter of 20% hydroxyapatite (HA) slurry, reaction tubes are further incubated for 15 minutes at 4°C, and then, centrifuged for 2 minutes at 15'000 g-force. Collected HA is washed with 250 micro liter of buffer 3 times, re-suspended 250 micro liter ethanol, and then transferred to a vial containing 5 ml of scintillate to measure radioactivity. Competitive binding assay: The competitive binding assay is carried out by using 20 fm of ^3H 9-cis-RA in the absence (100% binding) or presence of increasing concentrations (10^{-10} ~ 10^{-4} M) of e.g. HX531.

Experimental Part – Pharmacology

As used herein, pharmaceutical preparations are for enteral, such as oral, and also rectal or parenteral, administration to homeotherms, with the preparations comprising the pharmacological active compound either alone or together with customary pharmaceutical auxiliary substances. For example, the pharmaceutical preparations consist of from about 0.1 % to 90 %, preferably of from about 1 % to about 80 %, of the active compound. Pharmaceutical preparations for enteral or parenteral, and also for topical, e.g. ocular,

administration are, for example, in unit dose forms, such as coated tablets, tablets, capsules or suppositories and also ampoules. These are prepared in a manner that is known per se, for example using conventional mixing, granulation, coating, solubilizing or lyophilizing processes. Thus, pharmaceutical preparations for oral use can be obtained by combining the active compound with solid excipients, if desired granulating a mixture which has been obtained, and, if required or necessary, processing the mixture or granulate into tablets or coated tablet cores after having added suitable auxiliary substances.

The aforementioned pharmaceutical compositions may be prepared by the addition of pharmacologically and pharmaceutically acceptable additives. Examples of pharmacologically and pharmaceutically acceptable additives include, for example, excipients, disintegrators and disintegrating aids, binders, lubricants, coating agents, colorants, diluents, base materials, dissolving agents and dissolving aids, isotonic agents, pH modifiers, stabilizers, propellants, adhesives and the like.

The dosage of the active compound can depend on a variety of factors, such as mode of administration, homeothermic (warm blooded) species, age and/or individual condition.

Preferred dosages for the active ingredients of the pharmaceutical combination according to the present invention are therapeutically effective dosages, especially those which are commercially available.

Normally, in the case of oral administration, an approximate daily dose of from about 0.01 mg to about 1000 mg is to be estimated e.g. for a patient of approximately 75 kg in weight.

Typically, a representative of an RXR-antagonist of formula (I), will be supplied in the form of suitable dosage unit form, for example, a capsule or tablet, and comprising a therapeutically effective amount, e.g. from about 20 to about 320 mg, which may be applied to patients. The application of the active ingredient may occur up to three times a day, starting e.g. with a daily dose of 20 mg or 40 mg of active ingredient, increasing via 80 mg daily and further to 160 mg daily up to 320 mg daily. Preferably, active ingredient is applied twice a day with a dose of 80 mg or 160 mg, respectively, each. In a low-dose formulation, active ingredient with a dose of 20 mg or 40 mg may be used. Corresponding doses may be taken, for example, in the morning, at mid-day or in the evening. Preferred is b.i.d. administration.

The next paragraphs describe representative galenic formulations, comprising typically a pharmaceutically effective amount of a compound of formula (I).

Tablets:

Tablets, each comprising 50 mg of active ingredient according to the definition of formula (I) or a salt thereof, can be prepared as follows:

Composition (10 000 tablets)

active ingredient	500.0 g
lactose	500.0 g
potato starch	352.0 g
gelatin	8.0 g
talc	60.0 g
magnesium stearate	10.0 g
silicon dioxide (highly dispersed)	20.0 g
ethanol	q.s.

The active ingredient is mixed with the lactose and 292 g of potato starch and the mixture is moistened with an ethanolic solution of the gelatin and granulated through a sieve. After drying, the remainder of the potato starch, the magnesium stearate, the talc and the silicon dioxide are mixed in and the mixture is compressed to form tablets, each weighing 145.0 mg and comprising 50.0 mg of active ingredient; the tablets may, if desired, be provided with breaking notches for finer adaptation of the dose.

Sterile solution:

A sterile-filtered aqueous gelatin solution which comprises 20 % cyclodextrins as solubiliser and which comprises 3 mg of an active ingredient in accordance to this invention or of a salt, for example the sodium salt, thereof as active ingredient, is mixed under aseptic conditions, with heating, with a sterile gelatin solution that comprises phenol as preservative in such a manner that 1.0 ml of solution has the following composition:

active ingredient	3 mg
gelatin	150.0 mg

phenol	4.7 mg
dist. water with 20 % cyclodextrins as solubilizer	1.0 ml

Sterile dry substance for injection:

5 mg of one of the compounds of formula I mentioned in the working Examples as active ingredient are dissolved in 1 ml of an aqueous solution comprising 20 mg of mannitol and 20 % cyclodextrins as solubiliser. The solution is sterile-filtered and introduced under aseptic conditions into a 2 ml ampoule, is deep-frozen and lyophilised. Before use, the lyophilisate is dissolved in 1 ml of distilled water or 1 ml of physiological saline solution. The solution is administered intramuscularly or intravenously. This formulation can also be introduced into double-chamber injection ampoules.

Film coated tablets:

10 000 film-coated tablets, each comprising 100 mg of an active ingredient in accordance to this invention can be prepared as follows:

active ingredient	1000 g
corn starch	680 g
colloidal silicic acid	200 g
magnesium stearate	20 g
stearic acid	50 g
sodium carboxy-methyl starch	250 g
water	q. s.

A mixture of one of the compounds of formula I, e.g. as mentioned in the working Examples as active ingredient, 50 g of corn starch and the colloidal silicic acid is processed with starch paste consisting of 250 g of corn starch and 2.2 kg of demineralised water to form a moist mass. The moist mass is forced through a sieve having a mesh size of 3 mm and is dried at 45°C for 30 minutes in a fluidized bed dryer. The dried granules are pressed through a sieve having a mesh size of 1 mm, are mixed with a previously sieved mixture (1 mm sieve) of 330 g of corn starch, the magnesium stearate, the stearic acid and the sodium carboxymethyl starch, and are compressed to form slightly biconvex tablets.

In a manner analogous to that described above, it is also possible to prepare pharmaceutical preparations comprising a different compound according to any one of Experimental Part - Chemistry.

Experimental Part – Chemistry


The compounds of formula (I) can be prepared, for example, as described in the following reaction schemes and in the working examples.

Referential Examples

Synthesis of monosubstituted terephthalic acid monomethyl ester

The monosubstituted terephthalic acid monomethyl esters which were used in the foregoing examples as the raw materials may be synthesized as described in the following paragraphs.

Reaction scheme 1:



4-Dibromomethyl-3-fluorobenzoic acid (2)

A solution of 3-fluoro-4-methyl benzoic acid (1, 0.19 mol), N-bromosuccinimide (0.45mol) and benzoyl peroxide (9.1 mmol) in CCl_4 (360 ml) is refluxed for 36 hours (h). The reaction mixture is cooled to room temperature and filtered off. The residue is washed with CCl_4 and

the combined filtrates are concentrated to give crude 4-dibromomethyl-3-fluorobenzoic acid (2).

3-Fluoro-4-formyl benzoic acid (3)

AgNO₃ (0.39 mol) in hot H₂O (90 ml) is added dropwise to a solution of crude 4-dibromomethyl-3-fluorobenzoic acid (2, 0.19 mol) in ethanol (EtOH) (480 ml) at 50 °C over 10 min and then the mixture is stirred at the same temperature for 45 min. After cooling to room temperature, the mixture is poured into 1 N HCl (200 ml) and filtered off. The residue is washed with EtOH and the filtrate is concentrated to ca. 300 ml. The mixture is extracted twice with ethylacetate (EtOAc) and the combined organic layers are washed with brine, dried over MgSO₄ and evaporated *in vacuo*. The crystals are collected by filtration and washed with ether/hexane (1:1) to give 3-fluoro-4-formyl benzoic acid (3).

3-Fluoro-4-formyl benzoic acid methyl ester (4)

60% NaH (0.14 mol) is added portionwise to a solution of 3-fluoro-4-formyl benzoic acid (3, 0.12 mol) in dry DMF (330 ml). The mixture is stirred at room temperature for 30 min. Methyl iodide (0.14 mol) is added dropwise to the mixture. After stirring at room temperature for 5h, the reaction mixture is poured into 1 N HCl (ca. 1000 ml) and extracted twice with EtOAc. The combined organic layers are washed with saturated aqueous NaHCO₃, brine, dried over MgSO₄, and evaporated *in vacuo* to give crude 3-fluoro-4-formyl benzoic acid methyl ester (4).

2-Fluoroterephthalic acid 4-methyl ester (5)

A solution of 80 % NaClO₂ (0.13 mol) in H₂O (50ml) is added dropwise to a solution of crude 3-fluoro-4-formyl benzoic acid methyl ester (4, 0.12 mol) and sulfamic acid (0.13 mol) in H₂O (50 ml) and CH₃CN (100 ml). After stirring for 1h, the reaction mixture is poured into saturated Na₂SO₃ aqueous solution and 1 N HCl, and extracted three times with EtOAc. The combined organic layers are washed with brine, dried over MgSO₄, and evaporated *in vacuo*. The crystals are collected by filtration and washed with ether/hexane (1:1) to give 2-fluoroterephthalic acid 4-methyl ester (5) as white solid.

3-Fluoro-4-formyl benzoic acid benzyl ester (6)

60% NaH (0.23 mol) is added portionwise to a solution of 3-fluoro-4-formyl benzoic acid (3, 0.19 mol) in dry dimethylformamide (DMF) (570 ml). The mixture is stirred at room temperature for 45 min. Benzyl bromide (0.23 mol) is added dropwise to the mixture. After stirring at room temperature for 5h, the reaction mixture is poured into 1N HCl (ca. 1000 ml) and extracted twice with EtOAc. The combined extracts are washed with saturated aqueous NaHCO₃, brine, dried over MgSO₄, and evaporated *in vacuo* to give crude 3-fluoro-4-formyl benzoic acid benzyl ester (6).

2-Fluoroterephthalic acid 4-benzyl ester (7)

A solution of 80 % NaClO₂ (0.19 mol) in H₂O (100ml) is added dropwise to a solution of crude 3-fluoro-4-formyl benzoic acid benzyl ester (6, 0.19 mol) and sulfamic acid (0.19 mol) in H₂O (300 ml) and CH₃CN (150 ml). After stirring for 1h, the reaction mixture is poured into 1 N HCl and extracted three times with EtOAc. The combined organic layers are washed with brine, dried over MgSO₄, and evaporated *in vacuo*. Crystals are collected by filtration and washed with ether/hexane (1:1) to give 2-fluoroterephthalic acid 4-benzyl ester (7) as white solid.

2-Fluoroterephthalic acid 4-benzyl ester 1-methyl ester (8)

A solution of 2-fluoroterephthalic acid 4-benzyl ester (7) (0.14 mol) in SOCl₂ (60 ml) is stirred at 80 °C for 1h. The mixture is cooled to room temperature and concentrated *in vacuo* to give a crude 4-chlorocarbonyl-2-fluorobenzoic acid benzylester. A solution of the crude in toluene (30 ml) is added dropwise to a solution of triethylamine (0.27 mol) in methanol (MeOH) (200 ml) over 10 min. After stirring for 1h, the mixture is poured into 1 N HCl and extracted twice with EtOAc. The combined organic layers are washed with brine, dried over MgSO₄, and evaporated *in vacuo* to give crude 2-fluoroterephthalic acid 4-benzyl ester 1-methyl ester (8).

2-Fluoroterephthalic acid 1-methyl ester (9)

A solution of the crude 2-fluoroterephthalic acid 4-benzyl ester 1-methyl ester (8, 0.14 mol) in EtOH (210 ml) and EtOAc (210 ml) is treated with 10% Pd/C (4.0 g) under hydrogen atmosphere at room temperature for 5h. After filtration of the catalyst, the filtrate is evaporated *in vacuo*. Crystals are collected and washed with ether/hexane (1:1) to give 2-fluoroterephthalic acid 1-methyl ester (9) as white solid.

Following the procedures from 1 to 5, 2-fluoroterephthalic acid 1-methyl ester (9) is synthesized from 10.

The benzodiazepine-derivatives of the present invention may for example be synthesized as described in the following paragraphs. In addition, a synthesis of the comparative examples as known in the prior art is described as well.


Synthesis of a compound, for example, of formula (II c), wherein R_3 is CO- R_5 :

(2-Nitrophenyl)(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphtalen-2-yl)amine

The compounds of the present invention may be obtained by the synthetic procedure described in EP906'907, which is incorporated herein by reference.

The starting material (11) may for example be synthesized according to the procedures reported by Ebisawa et al (Chem. Pharm. Bull., 1999, 47(12), 1778-1786).

Reaction scheme 2:



Methyl(2-nitrophenyl)(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)amine ($R_4 = \text{CH}_3$) - (12)

60% NaH (0.41 mol) is added portionwise to a solution of (2-nitrophenyl)(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)amine (**11**, 0.27 mol) in dry DMF (1770 ml) at 0°C and stirred at room temperature for 45 min. To the mixture, methyl iodide (MeI) (30.6 mol) is added dropwise and the mixture is stirred at room temperature for 3 h. The reaction mixture is poured into ice water (ca. 2500 ml) and extracted with diethylether (Et_2O) (5 x 400 ml). The combined organic layer are washed with H_2O (2 x 400 ml), dried over MgSO_4 , and treated with SiO_2 (150 g). After evaporation of the solvent, the residue is loaded on a silica gel column. Flash column chromatography (2000 g of SiO_2 ; hexane/ $\text{EtOAc} = 10:1$) gives the title compound (**12**) ($R_4 = \text{CH}_3$).

N-Methyl-N-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-1,2-phenylenediamine ($R_4 = \text{CH}_3$) - (13)

A solution of methyl(2-nitrophenyl)(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)amine (12) ($R_4 = \text{CH}_3$, 0.26 mol) in EtOH (3200 ml) is treated with 10% Pd/C (8.9 g) under hydrogen atmosphere at room temperature for 2.5h. After filtration of the catalyst, the filtrate is evaporated to give the above diamine (13) ($R_4 = \text{CH}_3$).

N-{2-[Methyl(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)amino]phenyl}terephthalamic acid methyl ester ($R_4 = \text{CH}_3$, $Z = \text{H}$) – (14)

A solution of oxalyl chloride (0.41 mol) in dry CH_2Cl_2 (1800 ml) is added dropwise over 15 min to a suspension of mono-methyl terephthalate (0.41 mol) and pyridine (0.45 mol) in dry CH_2Cl_2 (4400 ml) at room temperature. After stirring for 50 min at the same temperature, the mixture is evaporated and dried in vacuo. The resulting white powder is added to a solution of N-methyl-N-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-1,2-phenylenediamine (13) ($R_4 = \text{CH}_3$, 0.27 mol) in dry pyridine (330 ml) and dry toluene (1200 ml) at room temperature. After stirring for 20 h, the mixture is cooled to 0 °C, treated with 2 N HCl (2400 ml) and filtered. The layers of the filtrate are separated, and the aqueous layer is extracted with EtOAc (2 x 600 ml). The combined organic layers are washed with saturated aqueous NaHCO_3 (600 ml) and brine (600 ml), and dried over MgSO_4 . The solution is treated with SiO_2 (180 g) and evaporated. The residue is loaded on a silica gel column. Flash column chromatography (2000 g of SiO_2 ; hexane/EtOAc = 5:1) gives the ester (14) ($R_4 = \text{CH}_3$, $Z = \text{H}$).

4-(5,7,7,10,10-Pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzocyclohepta[1,2-b]naphthalen-12-yl)benzoic acid methyl ester ($R_4 = \text{CH}_3$, $Z = \text{H}$) – (15)

A solution of N-{2-[methyl(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)amino]phenyl}terephthalamic acid methyl ester (14) ($R_4 = \text{CH}_3$, $Z = \text{H}$, - 0.23 mol) in dry CH_2Cl_2 (108 ml) is treated with polyphosphoric acid (980 g) at room temperature and the temperature is slowly elevated from room temperature to 110 °C over 50 min with removing CH_2Cl_2 by distillation. After stirring for 24h at 110 °C, the mixture is cooled to 0 °C, treated with H_2O (3000 ml) and extracted with EtOAc (4 x 800 ml). The combined organic layers are washed with brine (800 ml), dried over MgSO_4 , treated with SiO_2 (140 g), and evaporated. The residue is loaded on a silica gel column. Flash column chromatography (1600 g of SiO_2 ; hexane/EtOAc = 4:1) gives the ester (15) ($R_4 = \text{CH}_3$, $Z = \text{H}$) as yellow solid.

4-(5,7,7,10,10-Pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzocyclohepta[1,2-b]naphthalen-12-yl)benzoic acid methyl ester ($R_4 = \text{CH}_3$, $Z = \text{H}$) – (15)

A solution of N-methyl-N-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-1,2-phenylenediamine (**13**) (0.48 mol), terephthalic acid monomethyl ester (0.48 mol), and POCl_3 (0.95 mol) in dry toluene (1750 ml) is heated at 80 °C for 4 days. After cooling to room temperature, the mixture is diluted with EtOAc (1500 ml). The mixture is washed with 5 N NaOH, brine, dried over MgSO_4 and evaporated *in vacuo*. The residue is suspended in hexane. The crystals are collected by filtration and washed with hexane to give the ester (**15**) ($R_4 = \text{CH}_3$, $Z = \text{H}$) as yellow solid.

4-(2-Bromo-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzocyclohepta[1,2-b]naphthalen-12-yl)benzoic acid methyl ester ($R_4 = \text{CH}_3$, $Z = \text{H}$) – (16)

A solution of 4-(5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzocyclohepta[1,2-b]naphthalen-12-yl)benzoic acid methyl ester (**15**) ($R_4 = \text{CH}_3$, $Z = \text{H}$, 5.78 mmol) in CH_2Cl_2 (60 ml) is treated with pyridium tribromide (6.36 mmol) under nitrogen atmosphere at room temperature overnight. The reaction mixture is poured into aqueous Na_2SO_3 and extracted with CH_2Cl_2 . The organic layer is washed twice with 10% Na_2SO_3 , H_2O and brine and dried over MgSO_4 . After evaporation of the solvent, the residue is purified by flash column chromatography (SiO_2 ; hexane/EtOAc = 20:1) to give bromide (**16**) ($R_4 = \text{CH}_3$, $Z = \text{H}$).

4-(2-Acetyl-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzocyclohepta[1,2-b]naphthalen-12-yl)benzoic acid methyl ester ($R_4 = \text{CH}_3$, $Z = \text{H}$, $R_5 = \text{CH}_3$) – (19)

A mixture of 4-(2-bromo-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzocyclohepta[1,2-b]naphthalen-12-yl)benzoic acid methyl ester (**16**, $R_5 = \text{CH}_3$, $Z = \text{H}$, 1.9 mmol), butyl vinyl ether (4.8 mmol), $\text{Pd}(\text{OAc})_2$ (0.058 mmol), DPPP (0.11 mmol), K_2CO_3 (2.3 mmol), and H_2O (0.3 ml) in DMF (5 ml) is stirred at 120 °C for 1.5 h under nitrogen atmosphere. After cooling to room temperature, the mixture is poured into 1N HCl and extracted twice with EtOAc. The combined extracts are washed with H_2O , brine, dried

over MgSO_4 and evaporated *in vacuo*. The residue is purified by flash column chromatography (SiO_2 ; hexane: EtOAc = 9:1 to 3:1) to give the ester (19) ($R_4 = \text{CH}_3$, $Z = \text{H}$, $R_5 = \text{CH}_3$) as yellow solid.

4-[5,7,7,10,10-Pentamethyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-7,8,9,10-tetrahydro-5H-5,13-diazabenzocyclohepta[1,2-b]naphthalen-12-yl]benzoic acid methyl ester ($R_4 = \text{CH}_3$, $Z = \text{H}$) – (17)

A mixture of 4-(2-bromo-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzocyclohepta[1,2-b]naphthalen-12-yl)benzoic acid methyl ester (16) ($R_4 = \text{CH}_3$, $Z = \text{H}$, 4.8 mmol), bis(pinacolato)diboron (5.8 mmol), $\text{Pd}(\text{dppf})\text{Cl}_2$ (0.15 mmol) and KOAc (14 mmol) in dimethyl sulfoxide (DMSO) (20 ml) is stirred at 90 °C for 3.5h under nitrogen atmosphere. After cooling to room temperature, the mixture is poured into 1 N HCl and extracted twice with EtOAc. The combined organic layers are washed with brine, dried over MgSO_4 and evaporated *in vacuo*. The residue is purified by flash column chromatography (SiO_2 ; hexane:EtOAc = 8:1 to 4:1) to give the ester (17) ($R_4 = \text{CH}_3$, $Z = \text{H}$) as yellow solid.

4-[2-(4-Chlorobenzoyl)-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzocyclohepta[1,2-b]naphthalen-12-yl]benzoic acid methyl ester ($R_4 = \text{CH}_3$, $Z = \text{H}$, $R_5 = 4\text{-chlorophenyl}$) – (19)

A solution of 4-[5,7,7,10,10-pentamethyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-7,8,9,10-tetrahydro-5H-5,13-diazabenzocyclohepta[1,2-b]naphthalen-12-yl]benzoic acid methyl ester (17) ($R_5 = \text{CH}_3$, $Z = \text{H}$, 0.89 mmol) and phenyl boronic acid (1.8 mmol) in THF(= tetrahydrofuran)/MeOH (4:3, 14 ml) is treated with 2 N HCl (14 ml). After stirring for 5h, the mixture is extracted with EtOAc. The extract is washed with brine, dried over MgSO_4 and evaporated *in vacuo*. The resulting residue is purified by flash column chromatography (SiO_2 ; hexane: EtOAc 4:1 to 1:1) to give 12-(4-methoxycarbonylphenyl)-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzocyclohepta[1,2-b]naphthalene-2-boronic acid (18) ($R_4 = \text{CH}_3$, $Z = \text{H}$) contaminated with phenyl boronic acid.

A mixture of the above boronic acids, 4-chlorobenzoylchloride (1.6 mmol), $\text{Pd}(\text{PPh}_3)_4$ (0.040 mmol) and Cs_2CO_3 (2.0 mmol) in toluene (20 ml) is stirred at 90 °C for 9h under nitrogen atmosphere. After cooling to room temperature, the mixture is poured into 1 N HCl and

extracted twice with EtOAc. The combined organic layers are washed with, brine, dried over MgSO_4 and evaporated *in vacuo*. The residue is purified by flash column chromatography (SiO_2 ; hexane:EtOAc = 7:1) to give the ester (19) ($R_4 = \text{CH}_3$, $Z = \text{H}$, $R_5 = 4\text{-chlorophenyl}$) as yellow solid.


4-(2-Acetyl-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenz[4,5]cyclohepta[1,2-b]naphthalen-12-yl)benzoic acid ($R_4 = \text{CH}_3$, $Z = \text{H}$, $R_5 = \text{CH}_3$) - (20)

A solution of 4-[5,7,7,10,10-pentamethyl-2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-7,8,9,10-tetrahydro-5H-5,13diazabenz[4,5]cyclohepta[1,2-b]naphthalen-12-yl]benzoic acid methyl ester (19) ($R_4 = \text{CH}_3$, $Z = \text{H}$, $R_5 = \text{CH}_3$, 0.90 mmol) in THF/MeOH (3:1, 4 ml) is treated with 1 N NaOH (1 ml) and the mixture is stirred for 12h. The mixture is poured into 1 N HCl and extracted with EtOAc. The extract is washed with brine, dried over MgSO_4 and evaporated *in vacuo*. The resulting solids are collected by filtration and washed with ether/hexane (1:10) to give the benzoic acid (20) ($R_4 = \text{CH}_3$, $Z = \text{H}$, $R_5 = \text{CH}_3$) as yellow solid.

$^1\text{H-NMR}$ (CDCl_3) δ : 1.06 (3H, t), 1.14 (3H, s), 1.27 (3H, s), 1.32 (3H, s), 1.61-1.70 (4H, m), 2.59 (3H, s), 3.30 (3H, s), 6.89 (1H, s), 6.93 (1H, s), 7.01 (1H, d), 7.79 (1H, dd), 7.89 (1H, d), 7.93 (2H, d), 8.16 (2H, d).

$^1\text{H-NMR}$ ($\text{DMSO}-d_6$) δ : 0.91 (3H, t), 1.01 (3H, s), 1.15 (3H, s), 1.19 (3H, s), 1.45-1.55 (4H, m), 2.44 (3H, s), 3.16 (3H, s), 6.77 (1H, s), 6.98 (1H, s), 7.07 (1H, d), 7.63-7.69 (2H, m), 7.72 (1H, d), 7.93 (2H, d), 13.03 (1H, br).

Reaction scheme 3:



4-Amino-3-nitroacetophenone (**21**) is synthesized according to the procedures reported by Thomas C. Kuhler et al (Journal of Medicinal Chemistry., 1998, 41(11), 1777-1788) or WO96/33191.

3-Nitro-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-ylamino)acetophenone (22**)**

To a solution of 6-bromo-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene (48 mmol) and 4-amino-3-nitroacetophenone (**21**) (44 mmol) in THF (130 ml) are added $\text{K}_3\text{PO}_4 \cdot n\text{H}_2\text{O}$ (65 mmol), 2-(di-*t*-butylphosphino)biphenyl (2.2 mmol), and $\text{Pd}_2(\text{bda})_3$ (1.1 mmol) at room temperature. The reaction mixture is heated at 70 °C for 17h. After cooling, the mixture is filtered through Celite. The filtrate is diluted with H_2O and extracted with EtOAc. The organic layer is washed with 1 N HCl, brine, dried over MgSO_4 and evaporated *in vacuo*. The resulting solid is washed with Et_2O to give the acetophenone (**22**).

4-[Methyl(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)amino]-3-nitroacetophenone ($\text{R}_4 = \text{CH}_3$) – (23**)**

60% NaH (11 mmol) is added portionwise to a solution of 3-nitro-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-ylamino)acetophenone (**22**, 11 mmol) in dry DMF (36 ml) and stirred at room temperature for 45min. To the mixture, MeI (12 mmol) is added dropwise and the mixture is stirred at room temperature for 14h. The reaction mixture is poured into ice water and extracted twice with EtOAc. The combined organic layers are washed with H₂O, brine, dried over MgSO₄, and treated with SiO₂ (12 g). After evaporation of the solvent, the residue is loaded on a silica gel column. Flash column chromatography (200 g of SiO₂; hexane/EtOAc = 10:1) gives the acetophenone (**23**) (R₄ = CH₃).

3-Amino-4-[methyl(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)amino]acetophenone (R₄ = CH₃) – (24)

SnCl₂·2H₂O (21 mmol) is added to a solution of 4-[methyl(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)amino]-3-nitroacetophenone (**23**) (R₄ = CH₃, 4.3 mmol) in EtOAc (30 ml) and the mixture is heated at 80 °C for 1h. After cooling, to the reaction mixture are successively added crash-ice and 1N NaOH (55 ml). The reaction mixture is filtered through Celite (9g) and washed with EtOAc. The organic layer is washed with saturated aqueous NaHCO₃, brine, dried over MgSO₄ and evaporated *in vacuo*. The resulting solid is washed with hexane to give the amine (**24**) (R₄ = CH₃).

N-{5-Acetyl-2-[methyl(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)amino]phenyl}-3-fluoroterephthalamic acid methyl ester (R₄ = CH₃, Z = 3-F) – (25)

Oxalyl chloride (6.7 mmol) is added dropwise to a solution of 2-fluoroterephthalic acid 4-methyl ester (6.2 mmol), and 1 drop of DMF in dry CH₂Cl₂ (30 ml) at room temperature. After stirring for 2h, the mixture is concentrated *in vacuo*. The resulting residue in THF (15 ml) is added dropwise to a solution of 3-amino-4-[methyl(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)amino]acetophenone (**24**) R₄ = CH₃, 5.6 mmol), dry triethylamine (7.3 mmol) in dry THF (35 ml) at room temperature. After stirring for 2h, the mixture is treated with water and extracted three times with EtOAc. The combined organic layers are washed with saturated aqueous NaHCO₃, brine, and dried over MgSO₄. The solution is evaporated *in vacuo* and the residue is purified by flash column chromatography (100 g of SiO₂; hexane/EtOAc = 10:1 to 4:1) to give the ester (**25**) (R₄ = CH₃, Z = 3-F).

4-(2-Acetyl-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzocyclohepta[1,2-b]naphthalen-12-yl)-3-fluorobenzoic acid methyl ester ($R_4 = \text{CH}_3$, $Z = 3\text{-F}$) – (19)

A solution of N-{5-acetyl-2-[methyl(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)amino]phenyl}-3-fluoroterephthalamic acid methyl ester (**25**) ($R_4 = \text{CH}_3$, $Z = 3\text{-F}$, 0.57 mmol) in dry CH_2Cl_2 (0.5 ml) is treated with polyphosphoric acid (5 g) at room temperature and the temperature is slowly elevated from room temperature to 120 °C. After stirring at 120 °C for 1h, the mixture is cooled to room temperature, poured into crash-ice, and extracted twice with EtOAc. The combined organic layers are washed with saturated aqueous NaHCO_3 , brine, and dried over MgSO_4 . The extract is treated with SiO_2 (1.5 g), and evaporated. The residue is loaded on a silica gel column. Flash column chromatography (15 g of SiO_2 ; hexane/EtOAc = 10:1 to 2:1) gives the ester ($R_4 = \text{CH}_3$, $Z = 3\text{-F}$) – (19).

4-(2-Acetyl-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzocyclohepta[1,2-b]naphthalen-12-yl)-3-fluorobenzoic acid ($R_4 = \text{CH}_3$, $Z = 3\text{-F}$) – (20)

A solution of 4-(2-acetyl-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzocyclohepta[1,2-b]naphthalen-12-yl)-3-fluorobenzoic acid methyl ester (**19**) ($R_4 = \text{CH}_3$, $Z = 3\text{-F}$, 0.25 mmol) in the mixture of THF (2.5 ml) and MeOH (0.14 ml) is treated with 1N NaOH (0.41 ml) and the mixture is stirred for 12h. The mixture is poured into 1N HCl and extracted with EtOAc. The extract is washed with brine, dried over MgSO_4 and evaporated *in vacuo*. The resulting solids are collected by filtration and washed with Et_2O to give the acid (**20**) ($R_4 = \text{CH}_3$, $Z = 3\text{-F}$) as yellow solid.

$^1\text{H-NMR}$ ($\text{DMSO-}d_6$) δ : 1.00 (6H, s), 1.26 (6H, s), 1.53-1.62 (4H, m), 2.55 (3H, s), 3.29 (3H, s), 6.75 (1H, s), 7.03 (1H, s), 7.18 (1H, d), 7.71 (1H, d), 7.75 (1H, d), 7.81 (1H, dd), 7.90-7.98 (2H, m), 13.47 (1H, br).

In similar procedures described above, the following analogs are prepared.

4-(2-Acetyl-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenz[4,5]cyclohepta[1,2-b]naphthalen-12-yl)-2-fluorobenzoic acid ($R_4 = \text{CH}_3$, $Z = 2\text{-F}$) – (20)

$^1\text{H-NMR}$ ($\text{DMSO-}d_6$) δ : 1.04 (3H, s), 1.14 (3H, s), 1.25 (3H, s), 1.30 (3H, s), 1.56-1.65 (4H, m), 2.55 (3H, s), 3.27 (3H, s), 6.94 (1H, s), 7.10 (1H, s), 7.17 (1H, d), 7.54 (1H, dd), 7.66 (1H, dd), 7.78 (1H, dd), 7.81 (1H, d), 7.96 (1H, dd), 13.46 (1H, br).


4-(2-Acetyl-5-ethyl-7,7,10,10-tetramethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenz[4,5]cyclohepta[1,2-b]naphthalen-12-yl)benzoic acid, ($R_4 = \text{C}_2\text{H}_5$, $Z = \text{H}$) - (20)

$^1\text{H-NMR}$ ($\text{DMSO-}d_6$) δ : 1.13 (3H, s), 1.24 (3H, s), 1.26 (3H, t), 1.36 (3H, s), 1.41 (3H, s), 1.66-1.76 (4H, m), 2.66 (3H, s), 3.77-3.84 (2H, m), 3.90-3.98 (1H, m), 7.02 (1H, s), 7.18 (1H, s), 7.29 (1H, d), 7.86-7.90 (2H, m), 7.96 (2H, d), 8.16 (2H, d), 13.19 (1H, br).

4-(2-Acetyl-5-ethyl-7,7,10,10-tetramethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenz[4,5]cyclohepta[1,2-b]naphthalen-12-yl)-3-fluorobenzoic acid ($R_4 = \text{C}_2\text{H}_5$, $Z = 3\text{-F}$) – (20)


$^1\text{H-NMR}$ ($\text{DMSO-}d_6$) δ : 1.01 (6H, s), 1.18 (3H, t), 1.23 (3H, s), 1.28 (3H, s), 1.55-1.62 (4H, m), 2.55 (3H, s), 3.64-3.75 (2H, m), 3.86-3.94 (1H, m), 6.78 (1H, s), 7.02 (1H, s), 7.19 (1H, d), 7.72 (1H, d), 7.77 (1H, d), 7.82 (1H, dd), 7.90 – 7.97 (2H, m), 13.39 (1H, br).

By repeating the procedures described above using appropriate starting materials and conditions, the following compounds are obtained.

Example	Structure	R _f value (solvent)	MS ($M^+ + 1$)
1		0.22 ($\text{CHCl}_3:\text{MeOH}=9:1$)	481

2		0.20 (CHCl ₃ :MeOH=10:1)	499
3		0.23 (CHCl ₃ :MeOH=10:1)	499
4		0.23 (CHCl ₃ :MeOH=9:1)	495
5		0.19 (CHCl ₃ :MeOH=9:1)	513
6		0.28 (CHCl ₃ :MeOH=9:1)	495
7		0.33 (CHCl ₃ :MeOH=9:1)	577

Synthesis of a compound, for example, of formula (II c), wherein R₃ hydrogen and R₄ is C₃-C₇-alkenyl, or C₃-C₇-alkynyl, or C₂-C₇-alkanoyl:.

Reaction scheme 4:

4-(7,7,10,10-Pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzocyclohepta[1,2-b]naphthalen-12-yl)benzoic acid methyl ester (26)

4-(7,7,10,10-Tetramethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzocyclohepta[1,2-b]naphthalen-12-yl)benzoic acid (27)

A solution of 4-(7,7,10,10-tetramethyl-5-propyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzocyclohepta[1,2-b]naphthalen-12-yl)benzoic acid methyl ester (15) ($R_4 = C_3H_7$, 10 mmol) in 25% HBr-AcOH (35 ml) is heated at 90 °C for 17 h. After cooling to room temperature, the reaction mixture is poured into ice-water and extracted with EtOAc. The extract is washed with saturated aqueous $NaHCO_3$, brine, dried over $MgSO_4$, and evaporated *in vacuo*. The residue is purified by flash column chromatography (SiO_2 ; hexane/EtOAc = 3:1 to 0:1) to give the ester (26) and the acid (27).

4-(5-Acetyl-7,7,10,10-tetramethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzocyclohepta[1,2-b]naphthalen-12-yl)benzoic acid ($R_8 = CH_3$) – (29)

A solution 4-(7,7,10,10-tetramethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzocyclohepta[1,2-b]naphthalen-12-yl)benzoic acid (27) (0.47 mmol) and pyridine (1.2 mmol) in CH_2Cl_2 (4 ml) is treated with acetyl chloride (1.0 mmol) and stirred at


room temperature for 6 h. The mixture is poured into 1 N HCl and extracted with EtOAc. The extract is washed with brine, dried over MgSO_4 and evaporated *in vacuo*. The resulting solid is purified by reversed-phase HPLC (0.1% TFA, 30-100% gradient CH_3CN) to give the acid (29).

4-(5-Allyl-7,7,10,10-tetramethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenz[4,5]cyclohepta[1,2-b]naphthalen-12-yl)benzoic acid ($\text{R}_4 = \text{allyl}$) – (28)

60% NaH (4.2 mmol) is added portionwise to a solution of 4-(7,7,10,10-tetramethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenz[4,5]cyclohepta[1,2-b]naphthalen-12-yl)benzoic acid (27) (1.9 mmol) in dry DMF (7 ml) and stirred at room temperature for 45 min. Allyl bromide (9.4 mmol) and KI (4.2 mmol) are added to the mixture. After stirring for 13h, the reaction mixture is poured into ice-water and extracted with EtOAc. The extract is washed with brine, dried over MgSO_4 , and evaporated *in vacuo* to give a crude 4-(5-allyl-7,7,10,10-tetramethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenz[4,5]cyclohepta[1,2-b]naphthalen-12-yl)benzoic acid allyl ester.

A solution of the above crude in DMF (10 ml) is treated with 2 N NaOH (2 ml) and the mixture is stirred for 16h. The mixture is poured into 1 N HCl and extracted with EtOAc. The extract is washed with brine, dried over MgSO_4 and evaporated *in vacuo*. The resulting residue is purified by reversed-phase HPLC (0.1% TFA, 30-100% gradient CH_3CN) to give the acid (28) ($\text{R}_4 = \text{allyl}$).


By repeating the procedures described above using appropriate starting materials and conditions, the following compounds are obtained.

Example	Structure	R _f value (solvent)	MS ($\text{M}^+ + 1$)
8		0.40 ($\text{CHCl}_3:\text{MeOH}=10:1$)	463

9		0.33 (CHCl ₃ :MeOH=10:1)	465
10		0.18 (CHCl ₃ :MeOH=9:1)	467

Synthesis of a compound, for example, of formula (II c), wherein R₃ is cyano:

Reaction scheme 5:



3-Nitro-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-ylamino)benzonitrile (30)

To a solution of 6-bromo-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene (61.3 mmol) and 4-amino-3-nitrobenzonitrile (61.3 mmol) in THF (150 ml) are added NaOtBu (67.4 mmol), 2-(*t*-butylphosphino)biphenyl (6.13 mmol), and Pd₂(bda)₃ (3.06 mmol) at room temperature. The reaction mixture is heated at 80 °C for 2h. After cooling, the mixture is filtered through Celite. The filtrate is diluted with H₂O and extracted with EtOAc. The organic layer is dried over MgSO₄ and evaporated *in vacuo*. The resulting solid is washed with a mixture of hexane and EtOAc (8 : 1) to give (30).

4-[Methyl-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)amino]-3-nitrobenzonitrile (R₄ = CH₃) - (31)

NaH (60%, 6.44 mmol) is added portionwise to a solution of 3-nitro-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-ylamino)benzonitrile (30, R₄ = CH₃, 4.29 mmol) in DMF (15 ml) at 0 °C. The reaction mixture is slowly warmed up to room temperature and stirred for 1h. To the mixture is added dropwise MeI (6.44 mmol) and the reaction mixture is stirred at room temperature for 5h. The mixture is diluted with H₂O and extracted with Et₂O. The organic layer is dried over MgSO₄ and evaporated *in vacuo*. The resulting solid is washed with hexane to give 31 (R₄ = CH₃).

3-Amino-4-[methyl-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)amino]benzonitrile (R₄ = CH₃) - (32)

SnCl₂·2H₂O (0.17 mol) is added to a solution of 4-[methyl-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)amino]-3-nitrobenzonitrile (31) (R₄ = CH₃, 34.0 mmol) in EtOAc (125 ml) and the mixture is heated at 80 °C for 1h. After cooling, to the reaction mixture are successively added 6N NaOH (120 ml), H₂O (150 ml), and EtOAc (150 ml). The reaction mixture is filtered through Celite (25 g) and washed with EtOAc. The organic layer is dried over MgSO₄ and evaporated *in vacuo*. The resulting solid is washed with hexane to give 32 (R₄ = CH₃).

4-(2-Cyano-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenz[4,5]cyclohepta[1,2-b]naphthalen-12-yl)benzoic acid methyl ester ($R_4 = \text{CH}_3$, $Z = \text{H}$) – (33)

A mixture of 3-amino-4-[methyl-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)amino]benzonitrile (32) ($R_4 = \text{CH}_3$, 30.0 mmol), terephthalic acid monomethyl ester (30.0 mmol), POCl_3 (69.0 mmol), and toluene (200 ml) is heated at 80 °C for 3 days. After cooling, the reaction mixture is treated with 1 N HCl (100 ml) and H_2O (100 ml) and extracted with EtOAc. The organic layer is dried over MgSO_4 and evaporated *in vacuo*. The residue is purified by flash column chromatography (hexane:EtOAc = 5:1) to give 33 ($R_4 = \text{CH}_3$, $Z = \text{H}$).

4-(2-Cyano-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenz[4,5]cyclohepta[1,2-b]naphthalen-12-yl)benzoic acid ($R_4 = \text{CH}_3$, $Z = \text{H}$) – (34)

To a solution of 4-(2-cyano-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenz[4,5]cyclohepta[1,2-b]naphthalen-12-yl)benzoic acid methyl ester (33) ($R_4 = \text{CH}_3$, $Z = \text{H}$, 12.3 mmol) in DMF (15 ml) and THF (45 ml) is added 2 N NaOH (18.5 mmol) at room temperature. The reaction mixture is stirred at the same temperature for 1 day. The mixture is acidified by 1 N HCl (30 ml), diluted with H_2O , and extracted with EtOAc. The organic layer is dried over MgSO_4 and evaporated *in vacuo*. The resulting solid is washed with hexane and Et_2O to give 34 ($R_4 = \text{CH}_3$, $Z = \text{H}$).

$^1\text{H-NMR}$ (CDCl_3) δ : 1.08 (3H, s), 1.15 (3H, s), 1.28 (3H, s), 1.32 (3H, s), 1.61-1.72 (4H, m), 3.28 (3H, s), 6.90 (1H, s), 6.93 (1H, s), 6.99 (1H, d), 7.41 (1H, dd), 7.57 (1H, d), 7.90 (2H, d), 8.17 (2H, d).

In the similar procedures described above, the following analogues are prepared.

4-(2-Cyano-5-ethyl-7,7,10,10-tetramethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenz[4,5]cyclohepta[1,2-b]naphthalen-12-yl)benzoic acid ($R_4 = \text{C}_2\text{H}_5$, $Z = \text{H}$) – (34)

$^1\text{H-NMR}$ (CDCl_3) δ : 1.07 (3H, s), 1.16 (3H, s), 1.26 (3H, t), 1.27 (3H, s), 1.31 (3H, s), 1.62-1.71 (4H, m), 3.59-3.82 (2H, m), 6.90 (1H, s), 6.92 (1H, s), 7.00 (1H, d), 7.42 (1H, dd), 7.59 (1H, d), 7.92 (2H, d), 8.18 (2H, d).

4-(2-Cyano-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenz[4,5]cyclohepta[1,2-b]naphthalen-12-yl)-2-fluoro-benzoic acid ($R_4 = \text{CH}_3$, $Z = 2\text{-F}$) – (34)


$^1\text{H-NMR}$ ($\text{DMSO-}d_6$) δ : 1.05 (3H, s), 1.13 (3H, s), 1.26 (3H, s), 1.29 (3H, s), 1.56-1.69 (4H, m), 3.26 (3H, s), 6.95 (2H, s), 7.09 (1H, s), 7.22 (1H, d), 7.50 (1H, dd), 7.63-7.68 (3H, d), 7.92 (1H, t), 13.47 (1H, br s).

4-(2-Cyano-5-ethyl-7,7,10,10-tetramethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenz[4,5]cyclohepta[1,2-b]naphthalen-12-yl)-3-fluoro-benzoic acid ($R_4 = \text{C}_2\text{H}_5$, $Z = 3\text{-F}$) – (34)

$^1\text{H-NMR}$ ($\text{DMSO-}d_6$) δ : 1.08 (3H, s), 1.10 (3H, s), 1.24 (3H, t), 1.31 (3H, s), 1.35 (3H, s), 1.57-1.73 (4H, m), 3.68-3.79 (1H, m), 3.92-4.06 (1H, m), 6.87 (1H, s), 7.11 (1H, s), 7.32 (1H, d), 7.68-7.82 (3H, m), 7.99-8.04 (2H, m), 13.53 (1H, br s).

In the case of the N-allyl derivative **38**, the compound may be obtained as shown in the following scheme using appropriate starting materials and conditions.

Reaction scheme 6:




By repeating the procedures described above using appropriate starting materials and conditions, the following compounds are obtained.

Example	Structure	Rf value (solvent)	MS ($M^+ + 1$)
11		0.25 (Hexane:EtOAc=1:3)	464
12		0.30 (Hexane:EtOAc=1:3)	478
13		0.43 (CH2Cl2:MeOH=9:1)	492
14		0.24 (Hexane:EtOAc=1:5)	482
15		0.21 (Hexane:EtOAc=1:5)	496
16		0.27 (CHCl3:MeOH=9:1)	490

What is claimed is:

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof,




wherein R_1 and R_2 , independently of each other, represent hydrogen, or C_1 - C_7 -alkyl, or R_1 and R_2 together with the carbon atoms of the phenyl ring to which they bind form a 5-, 6- or 7-membered cycloalkyl ring, which ring may optionally be substituted by one or more C_1 - C_7 -alkyl groups, which alkyl groups may also together form one or more 3-, 4-, 5-, 6- or 7-membered rings;

R_3 represents -CN, -CO- R_5 , or hydrogen, provided that, if R_3 is hydrogen, R_4 must represent C_3 - C_7 -alkenyl or C_3 - C_7 -alkynyl;

R_5 represents aryl, or alkyl being unsubstituted or substituted by halogen, cyano, nitro, hydroxy, C_1 - C_7 -alkoxy, carboxyl or aryl.


R_4 represents C_1 - C_7 -alkyl, C_2 - C_7 -alkenyl or C_2 - C_7 -alkynyl or R_4 represents C_2 - C_7 -alkanoyl;

X represents ligand (a)




wherein Y may be in ortho, meta or para position and wherein Y represents carboxyl, C_1 - C_7 -alkoxy-carbonyl, aryloxy-carbonyl, tetrazolyl, SO_3H or $P(O)(OH)_2$; and wherein Z represents hydrogen or a substituent selected from the group consisting of C_1 - C_7 -alkyl, C_1 - C_7 -alkoxy, halogen, CF_3 , cyano and NO_2 .

2. Compound of claim 1, wherein R_1 and R_2 are positioned as illustrated in formula (IIa).



(II a).


3. Compound of claim 1 of formula (II b)



(II b),

wherein alk in each case represent C₁-C₇-alkyl.

4. Compound of claim 1 of formula (IIc).



(IIc).

5. Compound of claim 1, wherein X represents p-carboxyphenyl.
6. Compound of claim 1, wherein R₁ and R₂ form 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene ring; X represents 4-carboxy-phenyl; R₃ is cyano or C₂-C₅-alkanoyl; and R₄ represents C₁-C₇-alkyl, C₂-C₇-alkenyl or C₂-C₇-alkinyl.
7. Compound of claim 6, wherein for R₃ is in the para-position relative to NR₄ in formula (I).

8. Compound of claim 6, wherein R_4 represents C_1 - C_7 -alkyl and preferably methyl or ethyl.
9. A compound according to formula (I) or a salt thereof for use in the treatment of the human body.
10. Use of a RXR-antagonist, in particular in accordance to the definition of formula (I), in the manufacture of a medicament for delaying progression of, preventing of or treating a condition or disease being associated with RXR-antagonism, in particular selected from diabetes, type-2-diabetes, complication of diabetes such as retinopathy, nephropathy, neuropathy, and hyperlipidemia, obesity, dyslipidemia, and osteoporosis.
11. A pharmaceutical composition comprising a compound of claim 1 in association with a pharmacologically and pharmaceutically acceptable additive.
12. Method of of delaying progression of, preventing of or treating a condition or disease being associated with RXR-antagonism, which method comprises the steps of administering an effective amount of a RXR antagonist, which method comprises the steps of administering an effective amount of a compound of formula (I), or of a more preferred compound selected from the compounds according to formulae (V) and (VI), to a patient in need of such treatment, wherein said condition or disease associated with RXR-antagonism is preferably selected from the group consisting of diabetes, type-2-diabetes, complication of diabetes such as retinopathy, nephropathy, neuropathy, and hyperlipidemia, obesity, dyslipidemia, and osteoporosis.

Abstract

The present invention relates to novel benzodiazepine compounds exhibiting RXR-antagonist efficacy, to the manufacture and to the use thereof.

PCT/EP2004/003806



This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**